Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction







  • Outline



  • Goals of Therapy in Heart Failure and Reduced Ejection Fraction, 522




    • General Measures, 522




      • Diet and Fluid Restriction, 522



      • Activity, 522



      • Therapies to Avoid, 522




    • Diuretics and Management of Volume Status, 522




      • Loop Diuretics, 522



      • Thiazides and Thiazide-Like Diuretics, 525



      • Mineralocorticoid Receptor Antagonists and Potassium-Sparing Diuretics, 525



      • Vasopressin Antagonists, 525



      • Practical Issues in the Use of Diuretics in Heart Failure, 525



      • Risks of Diuretic Use, 525



      • Diuretic Resistance and Management, 526




    • Neurohormonal Antagonists in the Management of Heart Failure, 526



    • Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers, 527




      • Rationale/Pathophysiologic Basis for Use, 527



      • Effects on Hemodynamics, 528



      • Effects on Ventricular Structure, 528



      • Effects on Functional Capacity and Symptoms, 528



      • Effects on Morbidity and Mortality, 529



      • Mechanisms Underlying These Effects, 530



      • Side Effects, Complications, and Drug Interactions, 531



      • Practical Tips, 531




    • Angiotensin–Neprilysin Inhibition, 531




      • Practical Tips, 534




    • β-Blockers, 534




      • Rationale/Pathophysiologic Basis for Use, 534



      • Effects on Ventricular Structure, 534



      • Effects on Functional Capacity/Symptoms, 535



      • Effects on Morbidity and Mortality, 535



      • Side Effects, 536



      • Practical Tips, 537




    • Mineralocorticoid Receptor Antagonists, 537




      • Rationale/Pathophysiologic Basis for Use, 537



      • Effects on Ventricular Structure/Hemodynamics, 537



      • Effects on Morbidity and Mortality, 537



      • Side Effects, 538



      • Practical Tips, 538




    • Hydralazine and Nitrates, 538





    • Ivabradine, 539



    • Digoxin, 539




  • Future Directions, 540



  • Guidelines, 542


Heart failure (HF) is a complex clinical syndrome that represents a final common pathway for many types of cardiovascular disease. Multiple overlapping frameworks for classifying HF exist ( see also Chapters 18, Chapter 31 ). HF can be viewed as a continuum that is comprised of four interrelated stages as defined by the American College of Cardiology and the American Heart Association (ACC/AHA) Guidelines ( Fig. 37.1 ). Stage A patients represent the largest group, defined as patients who are at high risk for developing HF, but who do not yet have evidence of structural heart disease or symptoms of HF (e.g., patients with diabetes or hypertension; see also Chapter 35 ). Stage B includes patients who have structural heart disease, but without symptoms of HF (e.g., patients with a previous myocardial infarction [MI], left ventricular [LV] hypertrophy, or asymptomatic LV dysfunction). Stage C includes patients who have structural heart disease and have developed symptoms of HF. Stage D includes patients with refractory HF requiring special interventions (e.g., patients who may be candidates for advanced surgical therapies (LV assist devices or cardiac transplantation; see also Chapters 44, Chapter 45 ) or palliative care and hospice ( see also Chapter 50 ).




Fig. 37.1


American College of Cardiology and the American Heart Association stages of heart failure.

ACEI, Angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; DM, diabetes mellitus; EF, ejection fraction; GDMT, guideline-directed medical therapy; HF, heart failure; HRQOL, health-related quality of life; HTN, hypertension; ICD, implantable cardioverter-defibrillator; LV(H), left ventricular hypertrophy; MCS, mechanical circulatory support; MI, myocardial infarction.

Modified from Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol . 2009;53:e1–e90; and Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol . 2013;62:e147–e239.


Epidemiologically, a large (and growing) proportion of patients with symptomatic HF have normal or near normal ejection fraction (EF), so-called heart failure with preserved ejection fraction, or HFpEF. This clinical entity, for which effective therapies have yet to be developed with the possible exception of mineralocorticoid receptor antagonists (MRAs) in appropriately selected patients, is covered in detail in Chapter 39 . Similarly, acute decompensated HF leading to hospitalization is a major public health problem and is covered in detail in Chapter 36 . In the current chapter, we will focus on contemporary medical therapy for patients with symptomatic heart failure and reduced ejection fraction (HFrEF), with a focus on both the biologic rationale and the clinical evidence supporting contemporary treatment. Notably, few areas in medicine have seen as much progress in the development of effective new therapies over recent decades as has the treatment of HFrEF, with multiple classes of agents and devices (which are covered separately in Chapter 38 ) having demonstrated major improvements in morbidity and mortality over this period. Cumulatively, contemporary guideline-directed medical therapy has reduced mortality in HFrEF by more than 60% over the last 30 years ( Fig. 37.2 ).




Fig. 37.2


Mortality improvements for contemporary heart failure and reduced ejection fraction medications.

ACE Angiotensin-converting enzyme inhibitor; ARB , angiotensin receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; BB, β-blocker; MRA, mineralocorticoid receptor antagonist.




Goals of Therapy in Heart Failure and Reduced Ejection Fraction


The main goals of treatment in HF are to reduce symptoms, improve quality of life and functional capacity, prevent disease progression, and prolong survival. Although different therapies may impact each of these to varying degrees, collectively contemporary medical therapy for HFrEF has made a significant impact on each of these outcomes, as detailed later.


General Measures


Diet and Fluid Restriction


Dietary restriction of sodium (2–3 g daily) is commonly recommended in all patients with symptomatic HF, based on the rationale that sodium and fluid retention are a central aspect of HF pathophysiology. Although the recommendation for sodium restriction has been a long-standing cornerstone of HF management, the body of evidence on which these recommendations are based is relatively scant, and the level of evidence for fluid restriction in recent guidelines is based primarily on expert opinion only (class IIa recommendation, level of evidence C). Indeed, some studies have suggested that sodium restriction may actually worsen the neurohormonal profile and may lead to worsened outcomes. Strict fluid restriction is generally unnecessary in most patients unless the patient is hyponatremic (<130 mEq/L), a condition that may develop because of activation of the renin-angiotensin system, excessive secretion of arginine vasopressin (AVP), or loss of salt in excess of water from prior diuretic use. Fluid restriction (<2 L day) should be considered in hyponatremic patients or for those patients whose fluid retention is difficult to control despite high doses of diuretics and sodium restriction.


Activity


Regular physical activity or exercise training is recommended for HF patients (class I, level of evidence A) by the current ACC-AHA guidelines. This recommendation is based on studies and meta-analyses suggesting that exercise training improves functional capacity, quality of life, and clinical outcomes in patients with HF. Unlike many lifestyle interventions, exercise training has been rigorously studied in a large randomized outcomes trial of patients with HFrEF. HF-ACTION (A Controlled Trial Investigating Outcomes of Exercise Training) was a large multicenter randomized controlled study of exercise training that enrolled patients with an EF of 35% or less and New York Heart Association (NYHA) class II to IV symptoms with a primary endpoint of all-cause mortality and all-cause hospitalization. In this study, structured exercise training demonstrated a modest improvement in all-cause mortality and hospitalizations after adjustment for other variables, as well as improvements in functional capacity and quality of life. Notably, in the HF-ACTION study there was no evidence that exercise training in HF was unsafe, even in patients with relatively severe HF symptoms. Based on the results of HF-ACTION, cardiac rehabilitation for patients with HF is covered by the Centers for Medicare and Medicaid Services in the United States.


Therapies to Avoid


Several common classes of medications may exacerbate symptoms of HF, potentially lead to disease progression, and thus should be avoided in patients with heart failure. Nonsteroidal antiinflammatory drugs (NSAIDs) inhibit the synthesis of prostaglandins, lead to sodium and fluid retention, and may lead to worsening HF. Thiazolidinediones are a class of antidiabetic agents that may lead to fluid retention and have been shown to increase the rate of HF events in previous clinical trials. The antidiabetic therapy saxagliptin in the DPP-4 inhibitor medication class has also been shown to increase HF hospitalization, and similar concerns have also been raised about alogliptin. In general, the area of antidiabetes therapies in patients at risk for or with HF is in rapid evolution, and is discussed in more detail in Chapter 48 . Calcium channel blockers, which are frequently used for the management of hypertension and angina, have negative inotropic properties that may worsen HF and should generally not be used in patients with HF. The dihydropyridine calcium channel blockers (e.g., amlodipine) have been studied in HF, and although not efficacious as a HF therapy, appear to be safe in HF patients if needed for management of hypertension or angina. The use of dietary supplements should generally be avoided in the management of symptomatic HF because of the lack of proven benefit and the potential for significant interactions with proven HF therapeutics.


Diuretics and Management of Volume Status


Many of the cardinal clinical manifestations of HF result from excessive salt and water retention that leads to an inappropriate volume expansion of the vascular and extravascular space. Most patients with symptomatic chronic HF therefore require diuretic therapy to maintain appropriate volume status and to control symptoms related to fluid retention.


A number of classification schemes have been proposed for diuretics on the basis of their mechanism of action and their anatomic locus of action within the nephron. The most common classification for diuretics employs an admixture of chemical (e.g., “thiazide” diuretic), site of action (e.g., “loop” diuretics), or clinical outcomes (e.g., “potassium-sparing” diuretics).


Loop Diuretics


The loop diuretics are the primary form of diuretic used in patients with HF. These agents increase sodium excretion by up to 20% to 25% of the filtered load of sodium, enhance free water clearance, and maintain their efficacy unless renal function is severely impaired. The agents in this class, which include furosemide, bumetanide, and torsemide, act by reversibly inhibiting the Na + -K + -2Cl symporter (cotransporter) on the apical membrane of epithelial cells in the thick ascending loop of Henle ( Fig. 37.3 ), resulting in decreased urine sodium and chloride reabsorption with natriuresis and diuresis. The increase in delivery of Na + and water to the distal nephron segments also markedly enhances K + excretion, particularly in the presence of elevated aldosterone levels. Loop diuretics have a sigmoidal-shaped dose response relationship ( Fig. 37.4 ). Importantly, in both HF and renal insufficiency, the dose response for the loop diuretics curve shifts downward and to the right, thereby necessitating a higher dose to achieve the same effect and diminishing the likely maximal diuretic effect. The plasma concentration of loop diuretics also varies in peak value and duration of effect whether given intravenously or orally.




Fig. 37.3


Mechanisms of Loop Diuretic Action and Resistance. As shown in panel A, loop diuretics circulate bound to protein. As shown in panel B, they are secreted into the tubule lumen by organic anion transporters (OAT1 and OAT2) at the basolateral membrane and by multidrug resistance–associated protein 4 (and others) at the apical membrane. As shown in panel C, diuretics compete with chloride for binding to sodium–potassium–chloride cotransporter 2 (NKCC2), which is also present at the macula densa. Abnormalities at each step can mediate diuretic resistance.

From Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med . 2017;377:1964–1975.



Fig. 37.4


(A) Dose response curves of loop diuretics in normal versus patients with heart failure. (B) Comparison of pharmacokinetics of oral versus intravenous loop diuretics (LD ) . (C) An example of the braking phenomenon, whereby each additional dose of LD results in progressively less natriuresis. Each period of natriuresis is followed by a period of postdiuretic sodium retention. ADHF, Acute decompensated heart failure.

From Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med . 2017;377:1964–1975.


Because furosemide, bumetanide, and torsemide are bound extensively to plasma proteins, delivery of these drugs to the tubule by filtration is limited. However, these drugs are secreted efficiently by the organic acid transport system in the proximal tubule and thereby gain access to their binding sites on the Na + -K + -2Cl symporter in the luminal membrane of the ascending limb. Thus the efficacy of loop diuretics is dependent upon sufficient renal plasma blood flow and proximal tubular secretion to deliver these agents to their site of action. Although these drugs have similar mechanisms of action, they differ in terms of bioavailability and pharmacokinetics in ways that may have important clinical implications ( Table 37.1 ).


Thiazides and Thiazide-Like Diuretics


Thiazide-type diuretics inhibit the Na/Cl cotransporter in the distal tubule, thus blocking sodium resorption. Commonly used drugs in this class include hydrochlorothiazide, chlorthalidone, chlorothiazide, and metolazone (which is not technically a thiazide but has similar properties). Thiazides have been shown to be a potentially powerful adjunct to loop diuretics (so-called sequential nephron blockade), especially in patients demonstrating a substantial degree of diuretic resistance and/or with significant renal dysfunction. The potential benefits imparted by the addition of a thiazide-type diuretic must be balanced against the potential risks, specifically the risk of resulting electrolyte and metabolic abnormalities. Hypokalemia in particular is a frequent consequence of the sequential nephron blockade that results from combining a thiazide-type diuretic with a loop diuretic. Other electrolyte abnormalities, such as hyponatremia and hypomagnesemia, are also common and may be severe. Use of these agents as an adjunct to loop diuretics in the outpatient setting should generally be done with caution and only with careful monitoring.


Mineralocorticoid Receptor Antagonists and Potassium-Sparing Diuretics


MRAs, such as spironolactone and eplerenone, are relatively weak diuretics at commonly used doses, but are generally used in HF patients as neurohormonal antagonists rather than for their diuretic properties (as described in detail later). High doses of MRAs (e.g., doses of spironolactone of 100 mg/day or more) may induce substantial diuresis, and can be considered for use as a therapy for refractory diuretic resistance, although careful monitoring of potassium and renal function is required. A recent study of high-dose spironolactone for 96 hours in the acute HF setting was safe but did not improve natriuretic peptide levels, congestion, or clinical outcomes. Potassium-sparing diuretics such as triamterene are mild diuretics, but are typically not effective in HF patients and are seldom used clinically in this population.


Vasopressin Antagonists


Increased circulating levels of the pituitary hormone AVP contribute to increased systemic vascular resistance and positive water balance in HF patients. The cellular effects of AVP are mediated by interactions with three types of receptors: V 1a , V 1b , and V 2 . Selective V 1a antagonists block the vasoconstricting effects of AVP in peripheral vascular smooth muscle cells, whereas V 2 selective receptor antagonists inhibit recruitment of aquaporin water channels into the apical membranes of collecting duct epithelial cells, thereby reducing the ability of the collecting duct to resorb water. The AVP antagonists or vaptans were developed to selectively block the V 2 receptor (tolvaptan) or nonselectively block both the V 1a /V 2 receptors (conivaptan). These agents are not diuretics per se, but have been termed aquaretics because they lead to excretion of free water rather than natriuresis. Long-term therapy with the V 2 selective vasopressin antagonist tolvaptan did not improve mortality but appears to be safe when given chronically after a HF hospitalization. Several recent studies explored a potential role for improved short-term symptoms of dyspnea and measures of congestion with tolvaptan in the setting of acute HF, but these were neutral. The two vasopressin antagonists (conivaptan and tolvaptan) that are currently approved by the US Food and Drug Administration (FDA) are not specifically approved for HF, but are approved for the treatment of hyponatremia in patients with HF.


Practical Issues in the Use of Diuretics in Heart Failure


Patients with evidence of volume overload or a history of fluid retention should be treated with a diuretic to relieve their symptoms. In patients who have moderate to severe HF symptoms and/or renal insufficiency, a loop diuretic is generally required. Diuretics should generally be titrated as needed to relieve signs and symptoms of fluid overload. One commonly used method for finding the appropriate dose is to double the dose until the desired effect is achieved or the maximal dose of diuretic is reached. Patients with chronic HF can be instructed on parameters for self-adjustment of diuretics based on daily weights and symptoms ( see also Chapter 47 ). Although furosemide is the most commonly used loop diuretic, bumetanide or torsemide may be preferable in selected patients because of their increased bioavailability (see Table 37.1 ) and the potential antifibrotic effect of torsemide. Changing to torsemide in particular may induce diuresis in patients seemingly refractory to oral furosemide. With the exception of torsemide, the commonly used loop diuretics are short acting (<3 hours). For this reason, loop diuretics are usually more effective when given at least twice daily to minimize periods where the concentration in the tubular fluid declines below a therapeutic level, which may produce postdiuretic sodium retention or “rebound.” Infrequent dosing may therefore lead to sodium retention that exceeds natriuresis, especially if dietary sodium intake is not restricted. An ongoing large outcomes trial is investigating the strategy of torsemide versus furosemide in a broad population of patients with HF (ClinicalTrials.gov Identifier: NCT03296813).



TABLE 37.1

Pharmacokinetics of the Loop Diuretics

From Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol . 2012;59:2145–2153.



































































































Property Furosemide Bumetanide Torsemide
Relative IV potency 40 mg 1 mg 20 mg
Bioavailability (%) 10–100 (average = 50) 80–100 80–100
PO to IV conversion 2:1 1:1 1:1
Initial outpatient PO dose (mg) 20–40 0.5–1 5–10
Maintenance outpatient PO dose (mg) 40–240 1–5 10–20
Maximum daily IV dose (mg) 400–600 10 200
Onset (min)
Oral 30–60 30–60 30–60
Intravenous 5 2–3 10
Peak serum concentration after PO administration (hr) 1 1–2 1
Affected by food Yes Yes No
Metabolism 50% renal conjugation 50% hepatic 80% hepatic
Half-life (hr)
Normal 1.5–2 1 3–4
Renal dysfunction 2.8 1.6 4–5
Hepatic dysfunction 2.5 2.3 8
Heart failure 2.7 1.3 6
Average duration of effect (hr) 6–8 4–6 6–8


Risks of Diuretic Use


Observational studies have shown associations between loop diuretics, especially at higher doses, and adverse clinical outcomes in patients with HF. These observations are confounded by the fact that patients receiving higher doses of diuretics tend to have greater disease severity or comorbidity, making it difficult to determine whether higher doses of diuretics are simply a marker for greater HF severity or are actually causing harm in HF patients. Postulated mechanisms for worse outcomes with loop diuretics include stimulation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system, electrolyte disturbances, and deterioration of renal function. Although randomized data on the use of diuretics in HF are limited, the largest randomized study to date of diuretics in patients with acute decompensated HF (the DOSE study) did not suggest that higher doses of diuretics were associated with significant harm ( see also Chapter 36 ).


Patients with HF who are receiving diuretics should be monitored for complications of diuretics on a regular basis. The major complications of diuretic use include electrolyte and metabolic disturbances, volume depletion, and worsening azotemia. The interval for reassessment should be individualized based on severity of illness and underlying renal function; the use of concomitant medications such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and MRAs; the past history of electrolyte imbalances; and/or need for more aggressive diuresis.


Diuretic use can lead to potassium depletion, which can predispose the patient to significant cardiac arrhythmias and sudden death. Renal potassium losses from diuretic use can also be exacerbated by the increase in circulating levels of aldosterone observed in patients with advanced HF, and by the marked increases in distal nephron Na + delivery that follow use of loop or distal nephron diuretics. Serum potassium levels should generally be maintained between 4.0 and 5.0 mEq/L. Hypokalemia can be prevented by increasing the dietary intake of KCL, although most patients on significant doses of loop diuretics will require oral potassium supplementation. Diuretics may be associated with multiple other metabolic and electrolyte disturbances, including hyponatremia, hypomagnesemia, metabolic alkalosis, hyperglycemia, hyperlipidemia, and hyperuricemia.


Diuretic Resistance and Management


One inherent limitation of diuretics is that they achieve water loss via excretion of solute at the expense of glomerular filtration, which in turn activates a set of homeostatic mechanisms that ultimately limit their effectiveness. The term diuretic resistance typically defines a clinical scenario with progressively diminished responsiveness to diuretics despite persistent signs and/or symptoms of volume excess. One common cause of diuretic resistance is the so-called braking phenomenon to the effect of loop diuretics—this results from hemodynamic changes at the glomerulus mediated by the RAAS and sympathetic nervous system and adaptive changes in the distal nephron. Additionally, as mentioned previously, most loop diuretics, with the exception of torsemide, are short-acting drugs. Accordingly, after a period of natriuresis, the diuretic concentration in plasma and tubular fluid declines below the diuretic threshold. In this situation, renal Na + reabsorption is no longer inhibited and a period of antinatriuresis or postdiuretic NaCl retention ensues. If dietary NaCl intake is moderate to excessive, postdiuretic NaCl retention may overcome the initial natriuresis in patients with excessive activation of the adrenergic nervous system and renin-angiotensin system. Other potential contributors to apparent diuretic resistance include changes in cardiac or renal function or patient noncompliance with their diuretic regimen or diet. Concurrent use of drugs that adversely affect renal function, such as NSAIDs and cyclooxygenase-2 (COX-2) inhibitors, may contribute to diuretic resistance.


Management of patients with progressive resistance to diuretics requires careful consideration of potential causes. Increasing doses of diuretics to ensure that therapeutic concentrations are achieved in the tubule is the typical initial step. Another common method for treating the diuretic-resistant patient is to administer two classes of diuretic concurrently (“sequential nephron blockade”). Most commonly, this involves adding a thiazide-like diuretic to a loop diuretic. Many clinicians choose metolazone because its half-life is longer than that of some other distal collecting tubule diuretics, and because it has been reported to remain effective even when the glomerular filtration rate is low. As noted previously, careful monitoring of fluid status, renal function, and electrolytes is critical with this approach, because sequential nephron blockade can be associated with dramatic fluid shifts and electrolyte disturbances.


Neurohormonal Antagonists in the Management of Heart Failure


Maladaptive chronic activation of the renin-angiotensin-aldosterone axis and sympathetic nervous system is central to modern understanding of the pathophysiology of HF ( see Chapters 5, Chapter 6 ). The clinical development of drugs that antagonize these axes has been the most fundamental and important development in the management of chronic HF, establishing for the first time the ability of medical therapy to change the natural history of the disease process. In this regard, inhibitors of the RAAS (ACE inhibitors, ARBs [with and without neprilysin inhibition], and MRAs) and β-blockers have emerged as cornerstones of modern HF therapy for patients with HFrEF (see Fig. 37.1 ). The ability of therapies to effectively intervene on ventricular remodeling has been consistently shown to be the most reliable surrogate for predicting subsequent efficacy in improving clinical outcomes ( Fig. 37.5 ). These classes of agents, often collectively referred to as neurohormonal antagonists, have been shown to arrest, prevent, and even (particularly for β-blockers) potentially reverse the process of progressive ventricular remodeling that is associated with disease progression in HF ( Fig. 37.6 ). As described in detail later, these agents have a large evidence base definitively establishing their efficacy in improving morbidity and mortality in patients with chronic HF and reduced EF, which is summarized in the current ACC/AHA guidelines as “guideline-directed evaluation and management,” or GDEM (see Fig. 37.1 ).




Fig. 37.5


Relationship between drug effect on ventricular remodeling and mortality in randomized trials. Quantitative relationship between drug effects on end-diastolic volume and mortality: each data point represents a placebo-corrected change in end-diastolic volume (EDV) from an individual remodeling trial plotted against the mortality odds ratio (OR) for the specific therapy. Interventions were classified as favorable (blue circles) if the upper limit of the 95% confidence interval (CI) of the OR for death from the mortality trials was less than 1, neutral (black circles) if the 95% CI crossed 1, and adverse (red circles) if the lower limit of the 95% CI was greater than 1. There were significant correlations between short-term therapeutic effects on EDV and longer-term therapeutic effect on mortality. RCTs, Randomized clinical trials.

From Kramer DG, Trikalinos TA, Kent DM, et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010;56:392–406.



Fig. 37.6


The effect of angiotensin-converting enzyme (ACE) inhibitors and β-blockers on ventricular remodeling.

(A) and (B) Left ventricular end-diastolic volumes (LVEDV) (mean ± SE) in enalapril and placebo patients within the prevention trial and the previously reported treatment trial who had measurements made at all five time points. Measurements are at baseline, 4 months, 1 year, and at study end (mean of 25 months and 33 months for prevention trial and treatment trial patients, respectively). The final data point on each graph is after withdrawal (wd) of study drug for a minimum of 5 days. P values shown are for comparison of placebo and enalapril groups by repeated-measures analysis applied to all time points. Baseline volumes were significantly higher in treatment trial patients ( P < .005). In the prevention trial and the treatment trial, placebo-treated patients manifested progressive increases in ventricular volumes, whereas enalapril-treated patients showed an early and sustained reduction in LV volumes. Treatment difference between the placebo and enalapril groups was significantly greater within the treatment trial than within the prevention trial ( P < .02 at 1 year). (C) Effect of metoprolol succinate on LV volumes. Shown are the least square mean changes (SE) in LVEDVI (B) compared with the baseline for patients receiving metoprolol succinate 200 mg (triangles) , 50 mg (squares) , or placebo (diamonds) . ∗ P < .05 versus baseline. (D) Changes in LVEDVI from baseline (BL) to 6 months (6M) and 12 months (12M). Data are presented as mean value ± SE. P values comparing carvedilol and placebo are for repeated measures multivariate analysis of variance (MANOVA) over 12 months of treatment.

A and B, From Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD [Studies of Left Ventricular Dysfunction] Investigators. Circulation . 1993;88:2277–2283. C, From Colucci WS, Kolias TJ, Adams KF, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation . 2007;116:49–56. D, From Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol . 1997;29:1060–1066.


Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers


Rationale/Pathophysiologic Basis for Use


Activation of the RAAS plays a key role in the pathophysiology of the development and progression of HF. The fundamental biology of this neurohormonal axis as it relates to HF is covered in Chapter 5 . The RAAS may be inhibited at many levels: renin inhibition, inhibition of the conversion of angiotensin I to angiotensin II, antagonism of one or more angiotensin II receptors, and blockade of the primary target of aldosterone, the mineralocorticoid receptor.


Angiotensin-converting enzyme inhibitors


ACE inhibitors were the first agents clinically available for inhibiting the RAAS and continue to be the most widely used in clinical practice. ACE inhibitors interfere with the renin-angiotensin system by inhibiting the enzyme that is responsible for the conversion of angiotensin I to angiotensin II. These agents act by inhibiting one of several proteases responsible for cleaving angiotensin I to form angiotensin II. However, alternative enzymatic pathways have become recognized as playing a major role in angiotensin II production in humans. For example, in the failing human heart, angiotensin II formation is only partially inhibited by an ACE inhibitor but almost completely blocked by an inhibitor of chymase, another protease that catalyzes the formation of angiotensin II from angiotensin I. Accordingly, ACE inhibitor therapy achieves only partial inhibition of angiotensin II production.


To the extent that ACE inhibitors reduce production of angiotensin II, effects attributable to angiotensin II are diminished regardless of which receptor mediates the particular effect (i.e., both AT 1 and AT 2 receptors). ACE not only cleaves angiotensin I to form angiotensin II, but is also the principal protease that degrades bradykinin; thus ACE inhibition leads to increased levels of bradykinin within the circulation and at the tissue level. The hemodynamic effects of ACE inhibitors may be mediated in part through increases in regional bradykinin levels. Bradykinin stimulates endothelial release of nitric oxide (NO) and vasodilator prostaglandins, contributing to the vasodilator effects of ACE inhibitors. In some animal models of myocardial injury or pressure overload, the beneficial effects of ACE inhibitors mitigating cardiomyocyte hypertrophy and fibroblast hyperplasia within the myocardium are blocked by a bradykinin antagonist. Thus, reduction of bradykinin metabolism, resulting in potentiation of local bradykinin levels, potentially contributes to the therapeutic benefit of ACE inhibitors.


Angiotensin Receptor Blockers


Although ACE inhibitors and ARBs both inhibit RAAS, they do so by different mechanisms. ARBs block the effects of angiotensin II on the angiotensin type 1 receptor, the receptor subtype that is responsible for virtually all the adverse biologic effects relevant to angiotensin II on cardiac remodeling. In contrast to ACE inhibitors, effects of angiotensin II receptor antagonists limit the responses specifically mediated by that receptor. Because most of the clinically relevant effects of angiotensin II appear to be mediated through the AT 1 receptor, AT 1 receptor antagonists mirror the actions anticipated through the blockade of angiotensin II production. However, loss of feedback inhibition results in increased angiotensin II levels after administration of an AT 1 receptor antagonist, which leads to overstimulation of alternative angiotensin II receptors. The unopposed activation of non-AT 1 receptors may mediate some of the clinically relevant effects attributable to AT 1 receptor blockade. For example, stimulation of the AT 2 receptor may be responsible for the antiproliferative and antifibrotic effects of AT 1 antagonists within the cardiovascular system, although unopposed activation of the AT 2 receptor may also promote apoptosis.


Effects on Hemodynamics


The primary acute hemodynamic effect of both ACE inhibitors and ARBs is vasodilation. Early investigations of ACE inhibitors demonstrated that these agents produced dose-dependent decreases in right atrial pressure, pulmonary capillary wedge pressure, and systemic vascular resistance, with a resultant increase in cardiac index. In addition, inhibition of neurohormonal activation over time is evident from decreases in heart rates and plasma catecholamine levels at rest and with exercise. Similarly, ARBs produce dose-dependent decreases in right atrial pressure, pulmonary capillary wedge pressure, and systemic vascular resistance in association with increased cardiac index, which are sustained over time in the absence of tachyphylaxis. These hemodynamic effects of ARBs occur without increases in heart rate or neurohormonal activation. Beneficial hemodynamic and clinical effects of irbesartan were reported by Havranek and colleagues in patients already taking ACE inhibitors.


Effects on Ventricular Structure


In addition to a wealth of experimental evidence supporting the important role of the RAAS in the pathophysiologic processes of ventricular remodeling ( see Chapter 5 ), clinical evidence also supports this premise. Sharpe and associates demonstrated that captopril initiated within 48 hours after Q wave MI reduced the increase in LV end-diastolic volume after only 3 months of therapy. Similarly, in the multicenter Survival and Ventricular Enlargement (SAVE) trial, captopril improved survival among patients after MI with reduced left ventricular ejection fraction (LVEF) (<40%) and mitigated the degree of LV chamber dilation after the first year of therapy. ACE inhibitors prevent progressive LV remodeling in patients with LV systolic dysfunction with or without symptoms of HF (see Fig. 37.6 ). In a substudy of the Studies of Left Ventricular Dysfunction (SOLVD) trial, the placebo recipients exhibited LV dilation over the span of this study (1 year), whereas the enalapril recipients exhibited the opposite, which was consistent with a decrease in LV chamber size for a given LV pressure. This study demonstrated clinically that ACE inhibition prevents, and perhaps reverses, the extent of ventricular remodeling in patients with LV systolic dysfunction.


The precise effect of AT 1 receptor antagonists on ventricular remodeling is not as well studied. In the Evaluation of Losartan in the Elderly (ELITE) radionuclide substudy, researchers compared the effect of losartan, an AT 1 antagonist, with that of the ACE inhibitor captopril on LV remodeling in elderly patients with HF and systolic dysfunction (EF < 40%). After 48 weeks of therapy, captopril and losartan demonstrated statistically equivalent effects in reducing LV end-diastolic and end-systolic volumes, although there was a trend toward a greater beneficial effect of captopril in this study. Perhaps the largest study of whether combination therapy with an ACE inhibitor and ARB produces greater reduction in LV remodeling has been the Valsartan in Acute Myocardial Infarction Trial (VALIANT), in which investigators examined the effect of valsartan alone, captopril alone, and their combination in patients after an acute MI complicated by HF, LV dysfunction, or both. Although the patient population in this trial differed from that in HF trials (after MI, mean LVEF among the groups was 39%), the degree of LV remodeling (increase in LV end-diastolic volume and change in LVEF) was similar among all three groups of patients. The results of the VALIANT substudy do not support the view that combination therapy in patients with HF or LV dysfunction after MI exerts a greater effect in limiting LV remodeling than either class of agent alone.


Effects on Functional Capacity and Symptoms


Angiotensin-Converting Enzyme Inhibitors


Reduced functional capacity in patients with HF caused by systolic dysfunction results from a variety of cardiac and noncardiac factors. ACE inhibitors have variably been shown to improve exercise capacity in patients with HF and systolic dysfunction, presumably through their sustained hemodynamic benefits, as described previously. However, the improvement in exercise capacity noted with ACE inhibitors is often modest in clinical trials. The lack of more dramatic improvements in exercise capacity in clinical trials may result in part from improved survival among patients with advanced HF being treated with ACE inhibitors. For example, in the Vasodilators in Heart Failure Treatment (V-HeFT) II trial, in which ACE inhibition was compared with the combination of hydralazine and isosorbide dinitrate, subjects receiving the latter regimen had a more pronounced improvement in exercise capacity as judged by peak exercise oxygen consumption. However, the survival rate among patients treated with the ACE inhibitor was better than that among subjects taking hydralazine and isosorbide, which raised the question of whether more differentially better survival among patients treated with enalapril may have diluted any improvements in exercise capacity.


A number of studies have demonstrated that ACE inhibitors improve exercise time and ameliorate symptoms of HF. Taken together, these clinical data demonstrate that ACE inhibitors favorably influence symptoms of HF and exercise capacity in patients with LV systolic dysfunction.


Angiotensin Receptor Blockers


ARBs also improve exercise capacity and symptoms in patients with HF. Losartan has been shown to improve symptoms of HF after 12 weeks of therapy in patients with reduced LVEF (<45%). In a comparative trial with the ACE inhibitor enalapril, losartan-treated patients demonstrated similar exercise capacity and symptoms of HF after 12 weeks of treatment.


Riegger and colleagues studied the effects of various doses of the ARB candesartan (4, 8, and 16 mg) in patients with HF and LV systolic dysfunction. In this study, ACE inhibitors were withdrawn 2 weeks before the placebo run-in period. With all three doses of candesartan, patients demonstrated an improved HF symptoms score and improved exercise capacity in comparison with placebo-treated patients. Researchers in the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study compared candesartan alone, enalapril alone, and their combination over a 43-week period. Each agent resulted in similar improvements in exercise capacity and quality of life. Thus, available studies suggest that ARBs produce improvements in exercise capacity and HF symptoms that are similar to those produced by ACE inhibitors, either historically or in a direct, individual manner.


Effects on Morbidity and Mortality


Although the hemodynamic and clinical effects of ACE inhibitors are notably similar to those of ARBs, these two classes of agents should not be considered interchangeable, inasmuch as they possess both overlapping and distinct effects. Clinical evidence for the benefit of ACE inhibitors exceeds that for ARBs, a finding that is strongly influenced by the earlier development of ACE inhibitors. Results of clinical trials, both early and more recent, have helped determine whether, and under what circumstances, these agents can be used interchangeably or in combination.


Angiotensin-Converting Enzyme Inhibitors


ACE inhibitors were the first class of agents shown to significantly alter the natural history of HF, as demonstrated by a reduction in the frequency of death and of other morbid events. Most of these data have been accumulated from patients with reduced LVEF, and clinicians have therefore recognized the necessity for measuring ventricular systolic function and prescribing ACE inhibitors to patients with reduced EF (e.g., ≤35%) as standards of care for patients with HF. Table 37.2 lists the key trials demonstrating the benefit of ACE inhibitors in this population. These trials recruited a broad variety of patients, including women and the elderly, and patients with a wide range of causes and severity of LV dysfunction.



TABLE 37.2

Key Randomized Trials of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Heart Failure






































































































Trial Name Agent NYHA Class No. of Subjects Enrolled 12-Month Placebo Mortality (%) 12-Month Effect Size (%) P Value 12 Months (Full F/U)
ACEIs
HF
CONSENSUS-1 Enalapril IV 253 52 ↓31 .01 (.0003)
SOLVD-Rx Enalapril I–III 2569 15 ↓21 .02 (.004)
SOLVD-Asx Enalapril I, II 4228 5 0 .82 (.30)
Post-MI
SAVE Captopril 2231 12 ↓18 .11 (.02)
AIRE Ramipril 1986 20 ↓22 .01 (.002)
TRACE Trandolapril 1749 26 ↓16 .046 (.001)
ARBs
HF
VAL-HeFT Valsartan II–IV 5010 9 0 NS (.80)
CHARM-Alternative Candesartan II–IV 2028 NS NS NS (.02)
CHARM-Added Candesartan II–IV 2547 NS NS NS (.11)
HEAAL Losartan II–IV 3846 NS NS NS (.24)

ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CHARM , Candesartan Heart Failure: Assessment of Reduction in Mortality and Morbidity; CONSENSUS , Cooperative North Scandinavian Enalapril Survival Study; HEAAL , Heart Failure Endpoint Evaluation of Angiotensin II Antagonist Losartan; HF, heart failure; MI, myocardial infarction; NYHA, New York Heart Association; SOLVD, Studies of Left Ventricular Dysfunction; TRACE , Trandolapril Cardiac Evaluation; VAL-HeFT , Valsartan Heart Failure Trial.


The consistency of data from the SOLVD Prevention Study, SAVE, and Trandolapril Cardiac Evaluation (TRACE) has shown that asymptomatic patients with LV dysfunction (stage B) have less remodeling and a reduced risk of progressing to symptomatic HF when treated with ACE inhibitors. ACE inhibitors have also consistently shown benefit for patients with symptomatic LV dysfunction (stage C). All significant placebo-controlled ACE inhibitors in HFrEF patients have demonstrated a reduction in mortality. Further, the absolute benefit is greatest in patients with the most severe HF. Indeed, the patients with NYHA class IV HF in the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I) had a much larger effect size than the SOLVD Treatment Trial, which in turn had a larger effect size than the SOLVD Prevention Trial. Although only three placebo-controlled mortality trials have been conducted in patients with chronic HF, the aggregate data suggest that ACE inhibitors reduce mortality in direct relation to the degree of severity of chronic HF. A pooled analysis of placebo-controlled trials of ACE inhibitors suggested a 23% reduction in mortality and a 35% reduction in the combined endpoint of death or HF hospitalization compared with a placebo. The V-HeFT-II trial provided evidence that ACE inhibitors improve the natural history of HF through mechanisms other than vasodilation, inasmuch as subjects treated with enalapril had significantly lower mortality than subjects treated with the vasodilatory combination of hydralazine plus isosorbide dinitrate (which does not directly inhibit neurohormonal systems). Although enalapril is the only ACE inhibitor that has been used in placebo-controlled mortality trials in chronic HF, multiple ACE inhibitors have proven to be roughly equally effective when administered in oral form within the first week of the ischemic event in MI trials, supporting the general notion that the ACE inhibitor effect is a class effect in HF. In a direct randomized comparison study of high dose (≈35 mg of lisinopril) compared with low dose (≈5 mg of lisinopril), the Assessment of Treatment with Lisinopril and Survival (ATLAS) study suggested that mortality was similar, although higher doses were associated with lower rates of HF hospitalization.


Importantly, it should be emphasized that patients with low blood pressure (<90 mm Hg systolic) or impaired renal function (serum creatinine greater than 2.5 mg/mL) were not recruited or represent a small proportion of patients who participated in these trials. Thus the efficacy of these agents for these patient populations is less well established.


Mechanisms Underlying These Effects


The original hypothesis behind investigation of ACE inhibitors in patients with HF was that these agents would reduce the progression of clinical HF through vasodilation. As noted previously, direct comparison between ACE inhibitors and other vasodilatory regimens (e.g., nitrates and hydralazine in the V-HeFT studies) support the concept that ACE inhibitors alter the natural history of HF via mechanisms distinct from their hemodynamic effects, including direct effects on the cellular mechanisms responsible for progressive changes in the myocyte and the interstitium. Beyond an effect on clinical events linked to progressive HF, both the SOLVD and SAVE studies demonstrated significant reductions in the incidence of MI, which potentially contributed to the overall influence of ACE inhibitors on mortality. Furthermore, within the SOLVD population, enalapril caused a significant reduction in the number of patients hospitalized for unstable angina. These findings provided, for the first time, evidence of an influence of ACE inhibitors on the pathogenesis of acute coronary syndromes, an influence potentially mediated by effects on the arterial wall, on the balance between thrombosis and thrombolysis, or on both.


Angiotensin Receptor Blockers


In symptomatic HF patients who were intolerant of ACE inhibitors, the aggregate clinical data suggest that ARBs are roughly as effective as ACE inhibitors in reducing HF morbidity and mortality. Candesartan significantly reduced all-cause mortality, cardiovascular death, or hospitalization in ACE-intolerant patients in the Candesartan Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM-Alternative) trial. Similar findings were shown with valsartan in the small subgroup of patients not receiving an ACE inhibitor in the Valsartan Heart Failure Trial (Val-HeFT) ( Fig. 37.7 ). A direct comparison of ACE inhibitors and ARBs was assessed in the Losartan Heart Failure Survival Study (ELITE-II), which showed that losartan was not associated with improved survival in elderly HF patients when compared with captopril, but was significantly better tolerated. Two trials have evaluated ARBs compared to ACE inhibition in post-MI patients who developed LV dysfunction or signs of HF. The direct comparison of losartan with captopril indicated that losartan was not as effective as captopril on all-cause mortality, whereas valsartan was shown to be noninferior to captopril on all-cause mortality in the VALIANT study. 27 The combination of captopril and valsartan produced no further reduction in mortality in VALIANT, although the number of adverse events increased. When given in addition to ACE inhibitors in general cohorts of patients with symptomatic HF, the effects of ARBs were shown to have a modest beneficial effect in the CHARM-Added trial. However, the addition of valsartan to ACE inhibitors had no beneficial effect on mortality in Val-HeFT, although the combined endpoint mortality and morbidity was significantly (13.2%) lower with valsartan than with the placebo because of a reduction in the number of patients hospitalized for HF. The question of high-dose versus low-dose angiotensin receptor antagonism on clinical outcomes was evaluated in the Heart Failure Endpoint Evaluation of Angiotensin II Antagonist Losartan (HEAAL) trial. This study showed that the use of a high-dose losartan was not associated with a significant reduction in the primary endpoint of all-cause death or admission for HF (hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.84–1.04, P = .24) when compared with low-dose losartan, but was associated with a significant reduction in HF admissions (HR 0.94, 95% CI 0.84–1.04, P = .24), suggesting that uptitration of ARBs may confer clinical benefit.




Fig. 37.7


Outcomes with ARBs compared with the placebo in heart failure. (A) Kaplan-Meier curves for mortality in the valsartan (dotted line) and placebo (solid line) groups ( n = 185 and 181, respectively) without angiotensin-converting enzyme (ACE) inhibitor background therapy ( P = .017 by log-rank test) in the Valsartan Heart Failure Trial (Val-HeFT). (B) Kaplan-Meier cumulative event curves for the primary outcome (all-cause mortality, cardiovascular death, or hospitalization) in the Candesartan Heart Failure: Assessment of Reduction in Mortality and Morbidity trial (CHARM-Alternative) in ACE-intolerant patients.

A, From Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40:1414–1421; B, From Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–776.


Although one meta-analysis suggests that ARBs and ACE inhibitors have similar effects on all-cause mortality and HF hospitalizations, and although ARBs may be considered as initial therapy rather than ACE inhibitors following MI, the general consensus is that ACE inhibitors remain the first-line therapy for the treatment of HF, whereas ARBs are recommended for ACE inhibitor-intolerant patients. Importantly, a recent ACC/AHA/Heart Failure Society of America (HFSA) guideline update highlights that ACE inhibitors, ARBs, and now also angiotensin receptor-neprilysin inhibitors (ARNIs) have a class I recommendation for use in patients with chronic HFrEF in conjunction with other GDEMs (see further discussion later). Combination therapy with ACE inhibitors and ARB can be considered in persistently symptomatic patients, although the risk of side effects is higher (see later discussion), particularly in patients also treated with MRAs (the triple combination of ACE inhibitors, ARBs, and MRAs is specifically discouraged; class III recommendation for harm) in current guidelines.


Side Effects, Complications, and Drug Interactions


Angiotensin-Converting Enzyme Inhibitors


Most of the adverse effects of ACE inhibitors are related to suppression of the renin-angiotensin system. The decreases in blood pressure and mild azotemia that are often seen during the initiation of therapy are, in general, well tolerated and do not require a decrease in the dose of the ACE inhibitor. However, if hypotension is accompanied by dizziness or if the renal dysfunction becomes severe, it may be necessary to decrease the dose of the diuretic if significant fluid retention is not present, or alternatively, decrease the dose of the ACE inhibitor if significant fluid retention is present. Hyperkalemia may also become problematic if the patient is receiving potassium supplements or a potassium-sparing diuretic. Potassium retention that is not responsive to these measures may require a reduction in the dose of ACE inhibitor or (rarely) discontinuation. The side effects of ACE inhibitors that are related to kinin potentiation include a nonproductive cough (10%–15% of patients) and angioedema (1% of patients). In patients who cannot tolerate ACE inhibitors because of cough or angioedema, ARBs are the next recommended line of therapy. Patients intolerant to ACE inhibitors because of hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. The combination of hydralazine and an oral nitrate should be considered for these latter patients (see later discussion).


Early clinical evidence suggested that aspirin use may prevent or limit the hemodynamic and survival benefits of ACE inhibitors. Importantly, contemporary studies derived from registry data and population-based cohorts have refuted these earlier concerns related to a potential aspirin and ACE inhibitor interaction. In multiple recent systematic reviews of ACE inhibitor trials, improvement in clinical outcomes continued to be evident in patients receiving aspirin at baseline, although the magnitude of the benefit tended to be lower.


Angiotensin Receptor Blockers


ARBs are well tolerated and highly efficacious in patients who are intolerant of ACE inhibitors because of cough, skin rash, and angioedema and should therefore be used in symptomatic and asymptomatic patients with an EF less than 40% who are ACE inhibitor-intolerant for reasons other than hyperkalemia or renal insufficiency. Both ACE inhibitors and ARBs have similar effects on blood pressure, renal function, and potassium. Therefore, the problems of symptomatic hypotension, azotemia, and hyperkalemia will be similar for both of these agents. Although less frequent than with ACE inhibitors, angioedema has also been reported in some patients who receive ARBs. In patients who are intolerant to ACE inhibitors and ARBs, the combined use of hydralazine and isosorbide dinitrate may be considered as a therapeutic option in such patients.


Practical Tips


Angiotensin-Converting Enzyme Inhibitors


Starting and target doses for commonly used ACE inhibitors and ARBs are shown in Table 37.3 . Because fluid retention can attenuate the effects of ACE inhibitors, it is preferable to optimize the dose of diuretic first before starting the ACE inhibitor. However, it may be necessary to reduce the dose of diuretic during the initiation of an ACE inhibitor to prevent symptomatic hypotension. ACE inhibitors should be initiated in low doses, followed by increments in dose if lower doses have been well tolerated. Titration is generally achieved by doubling doses every 3 to 5 days. The dose of ACE inhibitors should be increased until the doses used are similar to those that have been shown to be effective in clinical trials or to the maximally tolerated dose. Higher doses are more effective than lower doses in preventing hospitalization based on the ATLAS trial. For stable patients, it is acceptable to add therapy with β-blocking agents before full target doses of ACE inhibitors are reached. Blood pressure (including postural changes), renal function, and potassium should be evaluated within 1 to 2 weeks after initiation of ACE inhibitors, especially in patients with preexisting azotemia, hypotension, hyponatremia, diabetes mellitus, or in those taking potassium supplements. Abrupt withdrawal of treatment with an ACE inhibitor may lead to clinical deterioration and should therefore be avoided in the absence of life-threatening complications (e.g., angioedema, hyperkalemia).



TABLE 37.3

Starting and Target Doses for Guideline-Recommended Drugs for Heart Failure and Reduced Ejection Fraction


















































































































Drug Initial Daily Dose(S) Maximum Dose(S) Mean Doses Achieved IN Clinical Trials
ACE Inhibitors
Captopril 6.25 mg 3 times 50 mg 3 times 122.7 mg/day
Enalapril 2.5 mg twice 10–20 mg twice 16.6 mg/day
Fosinopril 5–10 mg once 40 mg once N/A
Lisinopril 2.5–5 mg once 20–40 mg once 32.5–35.0 mg/day
Perindopril 2 mg once 8–16 mg once N/A
Quinapril 5 mg twice 20 mg twice N/A
Ramipril 1.25–2.5 mg once 10 mg once N/A
Trandolapril 1 mg once 4 mg once N/A
ARBs
Candesartan 4–8 mg once 32 mg once 24 mg/day
Losartan 25–50 mg once 50–150 mg once 129 mg/day
Valsartan 20–40 mg twice 160 mg twice 254 mg/day
Aldosterone Antagonists
Spironolactone 12.5–25.0 mg once 25 mg once or twice 26 mg/day
Eplerenone 25 mg once 50 mg once 42.6 mg/day
β-Blockers
Bisoprolol 1.25 mg once 10 mg once 8.6 mg/day
Carvedilol 3.125 mg twice 50 mg twice 37 mg/day
Carvedilol CR 10 mg once 80 mg once N/A
Metoprolol succinate extended release (metoprolol CR/XL) 12.5–25 mg once 200 mg once 159 mg/day
Hydralazine and Isosorbide Dinitrate
Fixed-dose combination 37.5 mg hydralazine/20 mg isosorbide dinitrate 3 times daily 75 mg hydralazine/40 mg isosorbide dinitrate 3 times daily ≈175 mg hydralazine/90 mg isosorbide dinitrate daily
Hydralazine and isosorbide dinitrate Hydralazine: 25–50 mg, 3 or 4 times daily and isosorbide dinitrate: 20–30 mg 3 or 4 times daily Hydralazine: 300 mg daily in divided doses and isosorbide dinitrate: 120 mg daily in divided doses N/A

Only gold members can continue reading. Log In or Register to continue

Jan 2, 2020 | Posted by in CARDIOLOGY | Comments Off on Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction
Premium Wordpress Themes by UFO Themes